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Copy number variations (CNVs) are implicated across many neurodevelopmental disorders (NDDs) and contribute to their shared
genetic etiology. Multiple studies have attempted to identify shared etiology among NDDs, but this is the first genome-wide CNV
analysis across autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia (SCZ), and obsessive-
compulsive disorder (OCD) at once. Using microarray (Affymetrix CytoScan HD), we genotyped 2,691 subjects diagnosed with an
NDD (204 SCZ, 1,838 ASD, 427 ADHD and 222 OCD) and 1,769 family members, mainly parents. We identified rare CNVs, defined as
those found in <0.1% of 10,851 population control samples. We found clinically relevant CNVs (broadly defined) in 284 (10.5%) of
total subjects, including 22 (10.8%) among subjects with SCZ, 209 (11.4%) with ASD, 40 (9.4%) with ADHD, and 13 (5.6%) with OCD.
Among all NDD subjects, we identified 17 (0.63%) with aneuploidies and 115 (4.3%) with known genomic disorder variants. We
searched further for genes impacted by different CNVs in multiple disorders. Examples of NDD-associated genes linked across more
than one disorder (listed in order of occurrence frequency) are NRXN1, SEH1L, LDLRAD4, GNAL, GNG13, MKRN1, DCTN2, KNDC1,
PCMTD2, KIF5A, SYNM, and long non-coding RNAs: AK127244 and PTCHD1-AS. We demonstrated that CNVs impacting the same
genes could potentially contribute to the etiology of multiple NDDs. The CNVs identified will serve as a useful resource for both
research and diagnostic laboratories for prioritization of variants.
npj Genomic Medicine            (2019) 4:26 ; https://doi.org/10.1038/s41525-019-0098-3
INTRODUCTION
Genomic copy number variations (CNVs) are structural variations
that involve deletions and/or duplications of segments of DNA.
Their impact is not necessarily harmful, but loss, increase, or
disruption of genes is often associated with, and can underlie
human disease, including neurodevelopmental disorders
(NDDs).1–6 Rare CNVs have been extensively studied in autism
spectrum disorder (ASD),7–9 attention deficit hyperactivity disorder
(ADHD),10 schizophrenia (SCZ),11,12 and less so, obsessive compul-
sive disorder (OCD).13,14 Various NDDs share genomic structural
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variations, including CNVs that perturb the same genes.1,15 For
example, deletions or duplications affecting coding sequences of
NRXN1 or CNTN6 have been implicated in ASD, ADHD, and
SCZ.16,17
A shared genomic etiology across multiple disorders is
supported through genome-wide association studies18 or analyz-
ing small loss-of-function (LoF) variations.19 However, CNV analysis
across disorders has been limited; e.g., ADHD and ASD,10 ASD and
SCZ,20 reviews on selected well-established genomic disorders
such as 16p11.2 deletions and duplications,21 or a meta-analysis of
CNVs on a single gene (NRXN116). To date, there has been no
genome-wide study of rare CNVs identified using an identical
technology, encompassing ASD, ADHD, OCD, and SCZ. An
identical method for interrogating CNVs across multiple disorders
increases the chance of finding rare CNVs with cross-disorder
implications. These could be missed if multiple technologies with
different detection sensitivities were applied.
This project was established to provide a public resource of CNV
samples with NDDs mostly from the province of Ontario, Canada,
all genotyped on same microarray platform: the Affymetrix
CytoScan HD platform, which consists of 1.9 million copy number
markers and 750,000 genotype-able single nucleotides poly-
morphisms. A CNV resource of control population samples was
published earlier under the Ontario Population Genomics
Platform.22
In creating this data resource, we aimed to: (i) catalogue CNVs
that are clinically relevant to each of ASD, ADHD, OCD, and SCZ,
and (ii) identify genes and loci with CNVs that are shared among
different NDDs. Where available, we analyzed whole genome
(WGS) or whole exome sequence (WES) data, in search of variants
that were not detected by microarray. The relevant genotypes and
CNVs are available in dbGaP (accession number phs001881.v1.p1)
and dbVar (accession number nstd173), respectively.
RESULTS
Sample description and detection of CNVs
We analyzed 4,460 samples ascertained for four NDDs; 2,691
(60.3%) were from individuals recruited because of the diagnosis
of one of these disorders, and the rest from apparently unaffected
family members (Table 1, Supplementary Table 1A). ASD, ADHD,
OCD, and SCZ cases were ascertained using criteria explained
previously (Supplementary Information).8,10,13,23,24 Childhood
onset OCD is not classically considered an NDD in the Interna-
tional Classification of Disease (ICD-11) or Diagnostic and
Statistical Manual of Mental Disorders (DSM-5), but in view of its
early onset, male preponderance and association with imaging
findings, we included OCD in this study as others often do.
Similarly, since SCZ has both neural and genetic correlates,
including some evidence of overlap or sharing genetic risk with
NDDs, we considered SCZ as well. The majority of samples (68.1%)
were ascertained for ASD, with the others distributed approxi-
mately equally among the other disorders. The male:female sex
ratio was almost 4:1 for ASD and ADHD, 2:1 for SCZ, and ~1:1 in
the pediatric OCD cases (Table 1). Different family structures were
sampled in the four sub-groups: some ASD and SCZ families
included multiple affected individuals; some OCD samples were in
trios (i.e., affected proband and both parents; details in Table 1,
Supplementary Table 1A). We did not genotype parents of cases
for ADHD (Table 1, Supplementary Table 1A). We defined a high
confidence set of CNVs (Supplementary Table 1B) as those
identified using two different detection algorithms, as previously
described.25 Rare variants were those with a frequency of less than
0.1% in a 10,851 subject population control sample genotyped in
multiple microarray platforms, including the Affymetrix CytoScan
HD.25 We also analyzed prioritized CNVs from our previous
publications on ADHD10 and SCZ.11,24 We had information with
respect to intellectual disability (ID) for some cases. ID including
borderline intellect and non-verbal learning disability was
comorbid with SCZ in 31/204 cases (16.9%),11 with ASD in 149/
599 cases (24.9%), and with ADHD in 3/427 cases (0.7%). No OCD
case had ID.
Clinically relevant CNVs
Clinically relevant CNVs included five categories: aneuploidies,
large CNVs ( > 3 Mb), CNVs consistent with known recurrent
genomic disorders, those impacting genes previously established
to be associated with NDDs, and all de novo CNVs (i.e., not found
in either parent) (details in Table 2). We found 306 clinically
relevant CNVs in 284 of 2,691 NDD cases (10.5%) (Tables 2, 3,
Supplementary Table 1C). Of these CNVs, 115 found in 111/2,691
cases (4.3%) were “clinically significant” or “likely clinically
significant” variants, as evaluated by expert clinical geneticists
according to American College of Medical Genetics and Genomics
guidelines.26 We did not find evidence for uniparental disomy. The
clinically relevant autosomal deletions, and chromosome X
deletions in females, were all single copy.
The first category included aneuploidies: trisomy 21, 47,XXY, 47,
XYY, and 45,X, found in 17/2,691 cases (0.63%), only among ADHD
or ASD cases (category A in Tables 2, 3; Fig. 1). The second CNV
category contained variants larger than 3 Mb, but excluding those
Table 1. Stratification of 4,460 samples in the cross-disorder CNV analysis
Disorder Samples1 Cases2 Adult 3 Sex ratio (male/female) Only probands4 Only one parent5 Trios6 Quartets7 Others8
ASD 3,034 1,838 4.0% 4.0 (1,474/366) 1,138 89 305 126 17
ADHD 427 427 0 3.7 (337/90) 427 0 0 0 0
SCZ 4359 20410 100% 2.0 (137/67) 155 36 13 0 0
OCD 564 222 0 0.9 (107/115) 49 6 167 0 0
All 4,460 2,691 10.3% 3.2 (2,055/638) 1,769 131 485 126 17
ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, SCZ schizophrenia, OCD obsessive compulsive disorder
1Count of all samples that passed our stringent QC, including assessing genotype quality, removing duplicated samples or those with non-mendelian
segregation implying alternative parental relationships. This includes parents, extended family members, and siblings. 2Includes probands and affected sibling
(s). Affected parents are not considered. 3Proportion of cases at least 18 years of age at the time of diagnosis (for schizophrenia) or time of DNA submission for
the microarray genotyping (for ASD (n= 73)). 4Includes affected individuals for whom parents were not sampled or failed QC. No parents were sampled for
ADHD. 5Affected individuals with one parent sampled or passed QC. 6Proband and both parents. 7Proband, one affected sibling and both parents. 8Families
with three or more affected individuals (15 families with three, one family with four, and one with five affected children) for ASD. 9Includes 231 samples of
extended family members or parents, including affected individuals. 10Of SCZ cases, 31 had intellectual disability
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associated with recurrent genomic disorders and aneuploidies
(category B in Tables 2, 3). We found these large variants in 23/
2,691 NDD cases (0.85%), with none among the OCD cases. The
third category was the variants associated with known recurrent
genomic disorders, found in 115/2,691 cases (4.3%; category C in
Tables 2, 3; Fig. 1). The most frequent were 16p13.11 duplications
(17 cases), 15q11.2 deletions (breakpoint (BP1-BP2) (16 cases),
and 15q11.2 duplications (BP1-BP2) (15 cases). Three distal
duplications of 16p11.2 were found in ADHD, ASD, and SCZ
cases. We found 15q11-q13 duplications in six cases diagnosed
with ADHD, ASD, OCD, or SCZ. The high prevalence of 15q11.2
duplications (BP1-BP2) and 16p13.11 duplications likely reflects
the relatively mild expression and reduced penetrance of these
genotypes.
Fourth, we identified de novo CNVs impacting genes in 35
cases: 31/448 (6.9%) for ASD and 3/167 (1.8%) for OCD (category D
in Tables 2, 3). Of 13 SCZ trios with data, we identified one de
novo genic CNV. Parents of ADHD cases were not analyzed, thus
no data on de novo CNVs were available for this disorder.
The last class of variants included inherited clinically relevant
CNVs that did not belong to any of the first three categories. These
included CNVs impacting genes previously implicated for NDDs
but either inherited or with unknown inheritance. We found these
variants in 117/2,691 cases (4.4%) (category E in Tables 2, 3).
Cases with more than one clinically relevant CNV
We found more than one clinically relevant CNV in 20/2,691
(0.74%) of NDD cases: 12/1,838 (0.65%) of ASD cases, 4/427
(0.95%) of ADHD cases; 3/222 (1.35%) of those with OCD, and 1/
204 (0.5%) of individuals with SCZ.
In ASD, there were eleven cases with two CNVs and one case
with three relevant variants. The latter, case 4-0040-003, had a
maternally inherited 53 kb deletion impacting CTNNA3, a mater-
nally inherited 54 kb duplication impacting CNTN4, and a de novo
547 kb duplication impacting YES1, ADCYAP1, and six other genes.
Examples with two clinically relevant CNVs each included: (i) a
male (7-0293-003) with a 611 kb deletion of 16p11.2 and a 513 kb
deletion of 15q11.2, of unknown inheritance; (ii) a female (2-1525-
003) with a maternally inherited 1.5 Mb deletion consistent with
the 16p13.11 recurrent microdeletion (neurocognitive disorder
susceptibility locus), and a de novo 326 kb duplication impacting
USP7, PMM2, C16orf72, and CARHSP1; and (iii) a male (2-0305-004)
with a maternally inherited 432 kb deletion in the 1q21.1 locus
associated with thrombocytopenia-absent radius syndrome and a
de novo 1.09 Mb duplication impacting GPD2 and NR4A2.
The four cases with ADHD with more than one CNV were all
male; each had two clinically relevant CNVs, all of unknown
inheritance. Examples included: (i) 213050 with Klinefelter
syndrome (47,XXY) and an autosomal 181 kb duplication affecting
MCPH1; (ii) 206760 with a 191 kb deletion impacting DLGAP2 and a
154 kb duplication involving DRD4 and eight more genes; and (iii)
235983S with Klinefelter syndrome (47,XXY) and an autosomal
123 kb duplication impacting DPP6.
Of the three OCD cases carrying more than one CNV, there was
one male (OCD146-JS-1254_188613) with three clinically signifi-
cant CNVs: a maternally inherited 143 kb deletion impacting
NLGN1, a second maternally inherited 115 kb deletion impacting
DPP6, and a paternally inherited 67 kb duplication impacting
PTPRN2. Another male (OCD125-896993) had a de novo 165 kb
deletion impacting ADRA2C and a paternally inherited 1.7 Mb
duplication impacting CNTN4 and CNTN6. A female (OCD109-1648)
had a maternally inherited 1.4 Mb deletion of 17p12 and a 190 kb
deletion impacting PTPRT. This case also had a de novo frameshift
deletion in LRCH2 (c.2190_2193del:p.C730fs; Supplementary Table
1C) identified using WES.
The only individual with SCZ having two clinically relevant CNVs
(Supplementary Table 1C) was a female (222720) with a 10.2 Mb
deletion of chromosome 5p congruent with the cri-du-chat
syndrome region, and a 7.3 Mb duplication of 6q26-27. Karyotyp-
ing confirmed this to be the result of an unbalanced
translocation.11
Cases with clinically relevant CNVs identified by microarray also
had SNVs or CNVs detected by WGS or WES
No WGS data were available for the ADHD and SCZ samples.
However, we have previously published WGS data for 106/209
(50.7%) ASD cases with clinically relevant CNVs.8,27,28 Of these, 15
had a clinically relevant LoF mutation and one had a 4.5 kb
deletion (Supplementary Table 1C). The latter case was a male (2-
1086-004) with a maternally inherited 80.1 kb duplication impact-
ing CTNND2, identified using array data. He also had paternally
inherited 4.5 kb deletion in ANO3, known to be associated with
autosomal dominant dystonia (OMIM: 610110). This deletion was
missed by microarray for lack of probes in this region, due to its
size (Supplementary Table 1C). Examples of LoF SNVs were: (i) a
female autism case (7-0133-003) with a 2.5 Mb de novo
duplication in 10q11.22-11.23 and a de novo nonsense mutation
in SOX5 (c.C313T:p.R105X). Mutations of SOX5 cause autosomal
dominant Lamb-Shaffer syndrome, characterized by global devel-
opmental delay and intellectual disability (OMIM:604975), and (ii) a
male autism case (7-0123-003) with a 2.9 Mb duplication involving
Table 2. Summary of cases carrying a CNV deemed relevant to neurodevelopmental disorders CNVs stratified by the disorder and variant type
Category ASD (%) ADHD (%) OCD (%) SCZ (%) All cases (%)
A: aneuploidies 11 (0.6) 6 (1.4) 0 0 17 (0.63)
B: large CNVs (>3 Mb)1 16 (0.9) 4 (0.9) 0 3 (1.5) 23 (0.85)
C: genomic disorder loci2 80 (4.3) 18 (4.2) 4 (1.8) 13 (6.4) 115 (4.3)
D: de novo3 31 (6.9) NA5 3 (1.8) 1 (NA)6 35 (5.6)
E: others4 89 (4.9) 14 (3.3) 8 (3.6) 6 (2.9) 117 (4.4)
Sum of unique samples across all categories7 209 (11.4) 40 (9.4) 13 (5.6) 22 (10.8) 284 (10.5)8
1This category included variants larger than 3Mb but not aneuploidies or variants of known recurrent genomic disorder loci larger than 3Mb, i.e., 15q11-13
duplication (Table 3, Supplementary Table 1C). 2Prevalence of known recurrent genomic syndromes in the general population is 0.8–1.0%. 3This category
includes de novo variants from aneuploidies, large CNVs and genomic disorder loci. The rate of de novo CNVs in the general population is 0.9–1.4%43. 4This
category included all other NDD relevant CNVs. 5Indicates that we did not sample parents of ADHD cases to establish inheritance pattern of variants. 6We
sampled only 13 trios; most SCZ samples were unrelated. Sum of the counts in each column is higher in some cases than the total number of cases with
relevant CNVs in the corresponding column, due to the fact that (i) some subjects might carry multiple relevant variants, and (ii) de novo category includes
CNVs from aneuploidy, large CNVs, and the genomic disorder loci. 7Numbers of prioritized CNVs for ASD, ADHD, OCD, and SCZ were 223, 43, 17, and 23,
respectively. 8Total number of prioritized CNVs across all cases was 306. The coordinates for clinically relevant CNVs are in Supplementary Table 1C
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Table 3. Copy number variations of clinical significance among four neurodevelopmental disorders
Category #1 Cytoband Type Size (kb) Sex Disorder Class2 Origin
A: aneuploidies (n= 17)
45,X 2 Xp22.33-q28 DEL 155,271 F ASD, ADHD, SCZA CS D, U
47,XX,+ 21/47,XY,+ 21 6 21p13-q22.3 DUP 48,130 F(2), M(4) ASD CS D, U(5)
47,XXY 5 Xp22.33-q28 DUP 155,271 M ASD(2), ADHD(3), SCZA CS U
47,XYY 4 Yp11.32-q12 DUP 59,374 M ASD(2), ADHD(2), SCZA CS D(2), U(2)
B: large CNVs ( > 3 Mb; n= 23) excluding aneuploidies (category A) and CNVs associated with known recurrent genomic disorders (category C)
46,XX,dup(2)(q23.3q24.1) 1 2q23.3-q24.1 DUP 3,071 F ASD VUS U
46,XY,del(3)(p14.1p13) 1 3p14.1-p13 DEL 5,301 M ASD LCS D
46,XY,dup(4)(q22.1q22.2) 1 4q22.1-q22.2 DUP 3,060 M ASD VUS U
46,XY,del(4)(q32.3) 2* 4q32.3 DEL 3,209 M ASD VUS U
46,XX,dup(4)(q34.3q35.1) 1 4q34.3-q35.1 DUP 3,886 F SCZ, SCZA VUS U
46,XY,dup(6)(q15q16.1) 1 6q15-q16.1 DUP 4,739 M ASD LCS M
46,XX,dup,(6)(p26q27) 1 6p26-q27 DUP 7,302 F SCZ, SCZA LCS U
46,XY,del(7)(q31.1q31.31) 1 7q31.1-q31.31 DEL 11,051 M ASD, SCZA CS D
46,XY,del(8)(p23.3p23.1) 1 8p23.3-p23.1 DEL 6,841 M ASD, SCZA CS U
46,XY,del(8)(p23.3p22) 1 8p23.3-p22 DEL 14,917 M ADHD CS U3
46,XY,del(8)(q12.3q13.2) 1 8q12.3-q13.2 DEL 3,278 M ASD LCS U
46,XY,del(8)(q24.21q24.22) 1 8q24.21-q24.22 DEL 4,945 M ADHD LCS U
46,XY,del(9)(p22.1p21.2) 1 9p22.1-p21.2 DEL 8,005 M ASD CS U
46,XY,del(13)(q14.13q14.3) 1 13q14.13-q14.3 DEL 5,350 M SCZ LCS U
46,XY,dup(15)(q25.3q26.1) 1 15q25.3-q26.1 DUP 6,519 M ASD LCS U
46,XY,dup(16)(q11.2q21) 1 16q11.2-q21 DUP 15,626 M ASD CS U
46,XY,dup(16)(q11.2q13) 1 16q11.2-q13 DUP 10,873 M ASD CS D
46,XX,dup(17)(q11.1q12) 1 17q11.1-q12 DUP 6,145 F ASD CS U
46,XY,del(18)(p11.32p11.21) 1 18p11.32-p11.21 DEL 15,264 M ASD CS U
46,XY,del(18)(q22.1q23) 1 18q22.1-q23 DEL 13,469 M ASD CS U
46,XX,dup(22)(q11.21q12.3) 1 22q11.21-q12.3 DUP 12,518 F ADHD CS U
46,XY,del(Y)(p11.2) 1 Yp11.2 DEL 3,140 M ADHD VUS U
C: CNVs associated with known recurrent genomic disorders (n= 115)
1q21.1 Proximal Deletion (TAR Syndrome) 3 1q21.1 DEL 410–513 M ASD VUS M(2), U
1q21.1 Distal Duplication 4 1q21.1-q21.2 DUP 1,817–2,034 F(2), M(2) ADHD, ASD(3), SZCA(2) CS M, U(3)
2q37.3 Deletion 1 2q37.3 DEL 5,275 F ADHD CS U
3q29 Deletion 1 3q29 DEL 2,603 M ASD CS U
4p16.3 Duplication 2ǂ 4p16.3 DUP 846-849 M ASD VUS P
5p Deletion (Cri-du-chat) 1 5p15.33-p15.2 DEL 10,191 F SCZ, SZCA(2) CS U
7q11.23 Deletion (WBS; includes ELN) 1 7q11.23 DEL 1,429 M ASD CS D
7q11.23 Duplication 1 7q11.23 DUP 716 M ASD VUS U
9q34.3 Duplication 1 9q34.3 DUP 2,064 M ASD LCS U
10q11.22-q11.23 Duplication 2* 10q11.22-q11.23 DUP 2,650–2,661 F ASD, SCZA VUS D
15q11-q13 Duplication 6 15q11.2-q13.1 DUP 4,918–6,158 F(2), M(4) ADHD, ASD(3), OCD, SCZ,
SCZA(6)
CS U
15q11.2 Deletion (BP1-BP2) 16 15q11.2 DEL 312–521 F, M(15) ADHD(3), ASD(12), OCD VUS M(4), U(12)
15q11.2 Duplication (BP1-BP2) 15 15q11.2 DUP 311–850 F(7), M(8) ADHD(3), ASD(12) LB M(2), P(2), U
(11)
15q13.3 Deletion 4 15q13.2-q13.3 DEL 1,533–2,072 F(2), M(2) ASD, SCZA CS P, U(3)
15q25 Distal Deletion 1 15q25.2-q25.3 DEL 959 F ASD VUS U
Rubinstein-Taybi Syndrome 1 16p13.3 DUP 204 M ASD VUS U
16p13.11 Deletion 3 16p13.11-p12.3 DEL 1,496–3,352 F, M(2) ADHD, ASD(2) CS, VUS(2) D, M, U
16p13.11 Duplication 17 16p13.11-p12.3 DUP 783–2,950 F(3), M(14) ADHD, ASD(12), OCD, SCZ(3),
SCZA
VUS M(3), P(3), U
(11)
16p12.1 Duplication 3 16p12.2 DUP 670–680 F, M(2) ASD VUS M(2), U
16p12.1 Deletion 3 16p12.2 DEL 613–655 M ADHD(2), ASD VUS U
16p11.2 Distal Duplication 3 16p11.2 DUP 273–362 F, M(2) ADHD, ASD, SCZ CS U
16p11.2 Distal Deletion 2 16p11.2 DEL 227–243 F, M ASD CS D, U
16p11.2 Proximal Duplication 1 16p11.2 DUP 625 M ADHD, ADHDA, SCZA(4) CS U
16p11.2 Proximal Deletion 4 16p11.2 DEL 598–746 F, M(3) ADHD, ASD(2), SCZ, SCZA CS U
17p12 Deletion 1 17p12 DEL 1,404 F OCD CS M
17p12 Duplication 2 17q12 DUP 1,858–1,970 M ADHD, ASD CS U
22q11.21 Deletion 7 22q11.21 DEL 1,396–3,154 F(3), M(4) ASD, SCZ(6), SCZA(6) CS U
22q11.21 Duplication 7 22q11.21 DUP 2,546–3,271 M ASD CS D, P, U(5)
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Table 3 continued
Category #1 Cytoband Type Size (kb) Sex Disorder Class2 Origin
22q11.2 Distal Duplication (LCR22-F to
LCR22-H)
1 22q11.22-q11.23 DUP 2,062 F ASD LCS U
22q13 Deletion 1 22q13.33 DEL 507 F ASD CS U
Xp22.3 Deletion 1 Xp22.3 DEL 1,681 M ADHD CS U
D: de novo (not in A to C; n= 23)
1q21.3 Deletion (PSMD4+ 3 genes) 1 1q21.3 DEL 98 M ASD VUS D
2q23.1 Deletion (MBD5+ORC4) 1 2q23.1 DEL 251 M ASD CS D
2q24.1 Duplication (NR4A2, GPD2) 1 2q24.1 DUP 1,090 M ASD VUS D
2q32.1-q32.2 Deletion (GULP1) 1 2q32.1-q32.2 DEL 328 F ASD VUS D
4p16.3 Deletion (ADRA2C) 1 4p16.3 DEL 165 M OCD VUS D
7p22.1 Deletion (AP5Z1, FOXK1) 1 7p22.1 DEL 44 M ASD VUS D
7p22.1 Deletion (FBXL18+ TNRC18) 1 7p22.1 DEL 130 M ASD VUS D
7q11.22 Deletion (AUTS2) 1 7q11.22 DEL 428 M ASD LCS D
7q36.3 Duplication (EN2, RBM33, CNPY1) 1 7q36.3 DUP 341 F ASD VUS D
8p23.3 Duplication (DLGAP2) 1 8p23.3 DUP 829 M ASD, SCZA LB D
10q11.21-q11.22 Duplication (ZFAND4,
MARCH8, WASHC2C)
1 10q11.21-q11.22 DUP 239 F OCD VUS D
16p13.2 Duplication (USP7+ 3 genes) 1 16p13.2 DUP 326 F ASD VUS D
16q23.3-q24.1 Deletion (ATP2C2+
22 genes)
1 16q23.3-q24.1 DEL 1,900 M ASD VUS D
17p13.3 Deletion (INPP5K, PITPNA, SLC43A2) 1 17p13.3 DEL 102 M ASD VUS D
17q25.3 Duplication (ACTG1+ 37 genes) 1 17q25.3 DUP 859 M ASD VUS D
17q25.3 Deletion (CSNK1D, SLC16A3) 1 17q25.3 DEL 63 M ASD VUS D
18p11.32 Duplication (COLEC12+ 7 genes) 1 18p11.32 DUP 547 F ASD VUS D
19q13.33 Duplication (GRIN2D, KCNC3,
PNKP+ 107 genes)
1 19q13.33 DUP 2,645 F ASD LCS D
21q22.3 Duplication (PDE9A+ 4 genes) 2^ 21q22.3 DUP 42–284 M ASD VUS D
22q11.23 Duplication (UPB1) 1 22q11.23 DUP 21 F SCZ VUS D
Xp22.31 Duplication (ANOS1, VCX3B) 1 Xp22.31 DUP 305 F OCD VUS D
Xp11.22 Deletion (SMC1A) 1 Xp11.22 DEL 24 F ASD CS D
E: CNVs not in categories A-D (n= 127)
1p36.33-p36.32 Deletion (SKI+ 61 genes) 1 1p36.33-1p36.32 DEL 1,779 M ASD CS U
1q21.1 Duplication (HFE2+ 19 genes)3 1 1q21.1 DUP 871 F ASD, SCZA VUS U
POGZ, PSMB4, SELENBP1 1 1q21.3 DUP 73 M ASD B U
DISC1 1 1q42.2 DUP 26 M ASD VUS U
NRXN1 10 2p16.3 DEL 35–658 F, M(9) ADHD, ASD(6), SCZ(3), SCZA(2) CS P(4), U(6)
DPP10 1 2q14.1 DEL 472 F ASD VUS P
CNTNAP5 1 2q14.3 DUP 1,043 M ASD VUS U
MBD5 1 2q23.1 DUP 315 M SCZ LCS U
MBD5 4 2q23.1 DEL 57-208 M ASD LCS M(2), P, U
CNTN4+ CNTN6 2 3p26.3-3p26.2 DUP 1,734–2,049 M ASD, OCD VUS P, U
CNTN4 1 3p26.3 DUP 54 F ASD VUS M
CNTN6 1 3p26.3 DEL 131 M ASD B U
SUMF1, ITPR1 1 3p26.1 DEL 277 M SCZ, SCZA CS M
GRM7 1 3p26.1 DUP 1,738 M ASD VUS U
NLGN1 1 3q26.31 DEL 142 M OCD VUS M
PAK2 2 3q29 DEL 31-37 M ASD VUS U
DLG1+ BDH1 1 3q29 DUP 341 M ASD LB U
ANKRD17+ COX18 1 4q13.3 DUP 236 M ASD LB M
GRID2 2 4q22.2 DEL 85–256 M ADHD, ASD VUS P, U
ANK2, PITX2+ 9 genes 1 4q25 DUP 2,841 F ASD, SCZA VUS U
CTNND2 2ǂ 5p15.2 DUP 81 M ASD VUS M
CTNND2 1 5p15.2 DEL 52 F ASD VUS U
MEF2C, TMEM161B 2 5q14.3 DUP 109–2,043 F, M ASD VUS U
MEF2C 1 5q14.3 DEL 272 F ASD VUS U
PTPRK 2ǂ 6q22.33 DEL 130-135 M ASD VUS U
LAMA2, ARHGAP18 1 6q22.33 DUP 1,064 M ASD VUS P
AUTS2 1 7q11.22 DUP 344 F ASD VUS M
ELN+ 4 genes 1 7q11.23 DUP 320 M ASD LCS U
GRM8 1 7q31.33 DEL 73 M ASD VUS U
CNTNAP2 1 7q35 DEL 135 M ASD LB M
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Table 3 continued
Category #1 Cytoband Type Size (kb) Sex Disorder Class2 Origin
KMT2C 1 7q36.1 DUP 440 F ASD LB U
DPP6, PAXIP1, HTR5A 3 7q36.2 DUP 123–1,800 M ADHD, ASD(2) VUS M, U(2)
DPP6 3 7q36.2 DEL 52–396 M ADHD, ASD, OCD, SCZA VUS M, P, U
PTPRN2, ESYT2, NCAPG2 3 7q36.3 DUP 50–430 M ADHD, ADHDA, ASD, OCD LB M, P, U
DLGAP2, CLN8, ARHGEF10 3 8p23.3 DUP 317–358 M ASD VUS P
DLGAP2 2 8p23.3 DEL 58–191 M ADHD, ASD VUS U
MCPH1 2 8p23.2-8p23.1 DUP 181–272 M ADHD, OCD LB M, U
PTPRD 1 9p24.1 DEL 81 M ASD VUS U
ASTN2, TRIM32, PAPPA 3 9q33.1 DEL 25–523 F, M(2) ADHDA(2), ASD VUS U
PCDH15 2 10q21.1 DEL 58–291 F, M ASD VUS U
CTNNA3 7 10q21.3 DEL 53–306 F(2), M(5) ASD B M(3), P, U(3)
10q24.32 Duplication (POLL, BTRC, DPCD) 1 10q24.32 DUP 226 M ASD LCS P
DRD4+ 8 genes 1 11p15.5 DUP 154 M ADHD VUS U
PAX6, ELP4 1 11p13 DUP 393 M ADHD VUS U
SHANK2 1 11q13.4 DEL 132 M ASD LCS M
DLG2 1 11q14.1 DEL 210 F ASD VUS U
CNTN5 1 11q22.1 DUP 25 M ASD VUS U
KMT2A+ 6 genes 1 11q23.3 DUP 265 F ASD VUS M
CACNA1C 1 12p13.33 DUP 56 M ASD VUS P
PCDH9 1 13q21.32 DUP 1,006 M ASD VUS M
CHD8 1 14q11.2 DUP 23 M ASD VUS P
NRXN3 3± 14q31.1 DEL 224–254 F, M(2) ASD LCS P(2), U
15q13.1-q13.2 Duplication (APBA2+
4 genes)
1 15q13.1-q13.2 DUP 1,376 M ASD VUS M
CHRNA7 1 15q13.3 DEL 441 F ASD LCS P
RBFOX1 1 16p13.3 DEL 103 F ASD, SCZA(2) VUS U
RBFOX1 2 16p13.3 DUP 42–373 M ASD VUS U
16p11.2 Duplication (ATP2A1+ 20 genes) 1 16p11.2 DUP 962 F ASD VUS U
ATP2C2+ 11 genes 1 16q24.1 DUP 1,061 F ASD VUS U
ATP2C2, TLDC1 3 16q24.1 DEL 23–126 M ADHD LB U
ANKRD11+ 5 genes 1 16q24.3 DUP 250 M ASD VUS U
NF1+ 14 genes 3 17q11.2 DUP 83–1,394 F, M(2) ADHD, ASD, SCZ LCS, VUS(2) P, U(2)
DLGAP1 1 18p11.31 DUP 62 M OCD VUS P
CDH7, CDH19 1 18p22.1 DEL 2,126 F OCD VUS M
MACROD2 1 20p12.1 DUP 22 M ASD VUS U
MACROD2 2 20p12.1 DEL 72–237 M ADHDA(2), ASD, OCD, SCZA VUS U
PTPRT+ 6 genes 1 20q12-q13.12 DUP 836 M ASD, SCZA VUS U
PTPRT 1 20q12 DEL 190 F OCD VUS U
22q11.21 Deletion (SNAP29, LZTR1+
12 genes)
1 22q11.21 DEL 749 M ADHD LCS U
CACNA1I 1 22q13.1 DUP 116 M ASD VUS U
ARSE+ 7 genes 2 Xp22.33-Xp22.32 DUP4 2,262 M ASD VUS P
ANOS1+ 4 genes 1 Xp22.31 DUP 1,247 F OCD VUS U
PTCHD1-AS+ 5 genes 5 Xp22.11 DEL 81–1,169 M ADHDA, ASD VUS M(4), U
IL1RAPL1 1 Xp21.3-Xp21.2 DUP 546 M ASD LCS M
DMD, TAB3, FTHL17 2 Xp21.2-Xp21.1 DUP 252–792 M ASD LCS,VUS M
RAB38B+ 8 genes 1 Xq28 DUP 286 F ADHD VUS U
WBS Williams-Beuren Syndrome, F female, M male, DEL deletion, DUP duplication, ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder,
SCZ schizophrenia, OCD obsessive compulsive disorder, VUS variants of unknown significance, B benign, LB likely benign, CS clinically significant, LCS likely
clinically significant, M maternally inherited, P paternally inherited, U unknown inheritance, D de novo. 1Number of subjects carrying CNVs in the indicated
cytoband. 2Clinical impact of variants was evaluated according to accepted clinical guidelines. 3Mosaic CNV. 4These two duplications are in two brothers. qPCR
showed that the father was also carrying these duplications on chromosome X, which implies that there might be translocation between X and an unknown
autosome, which then was transmitted to these two boys. We did not attempt identify the location of this duplication on autosomes. AIndicates the presence
of a similar CNV detected in a subject published previously as part of two large-scale schizophrenia CNV studies (Costain et al. 24 and Lowther et al.11) and one
ADHD study (Lionel et al.10). Sex, size of CNVs, inheritance, and the clinical classifications of these CNVs were not provided
Only genes whose coding sequences are impacted by CNVs are shown. However, CNVs impacting exons (UTRs) in MBD5 and PTCHD-AS were indicated
*Monozygotic pair of twins from two different families; ǂSiblings; ^two duplications from one case. ±two of these deletions are paternally inherited in siblings
diagnosed with ASD (one male, one female)
The coordinates for clinically relevant CNVs are in Supplementary Table 1C
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the 16p13.11 recurrent microduplication who also had a de novo
splice-site variant impacting SHANK3 (c.2223+ 1 G > A), which is a
gene strongly associated with NDDs.8 Of 13 OCD cases with
clinically relevant CNVs, three also had clinically relevant LoF
mutations previously identified using WES (Supplementary Table
1C).13 One example is a male OCD case (OCD146-JS-1254_188613)
with three clinically relevant CNVs: a maternally inherited 142 kb
deletion in 3q26.31, a maternally inherited 115 kb deletion in
7q36.2, and a paternally inherited 67 kb duplication in 7q36.3. He
also had three clinically relevant SNVs found by WES: (i) a
maternally inherited frameshift deletion in AFF2 (c.2976_2988del:
p.992_996del), which is an X-linked recessive variant associated
with mental retardation (OMIM:300806), (ii) a maternally inherited
frameshift deletion in DRD4 (c.233_245del:p.A78fs), an autosomal
dominant variant associated with autonomic nervous system
dysfunction and ADHD (OMIM:126452), and (iii) a maternally
inherited frameshift in MBD4 (c.939_940ins:p.E314fs), a gene
involved in DNA methylation (OMIM:603574).
Complex phenotypes
Because we had clinical information on NDD phenotypes beyond
the primary diagnoses for some cases, we investigated the
pleiotropy of CNVs shared among different NDDs (Supplementary
45,X
47,XYY
47,XXY
Trisomy 21
disorder SCZ OCD ADHD ASD
15q11−q13 DUP
16p13.11 DUP
16p11.2 Dist DUP
16p11.2 Prox DEL
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22q11 DEL
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16p13.11 DEL
16p12.1 DEL
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15q11.2 DUP (BP1−BP2)
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17q12 DEL
Xp22.31 DEL (STS)
2q37.3 DEL
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Fig. 1 Distribution of a) aneuploidies and b) known recurrent genomic disorder CNVs found in cases diagnosed with autism spectrum
disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia (SCZ), or obsessive compulsive disorder (OCD). Details of the
copy number variants, sex, and variant sizes are in Table 1, Supplementary Table 1A. DEL deletion, DUP duplication, TAR Thrombocytopenia-
Absent Radius syndrome locus, STS includes STS, BP breakpoint, LCR low-copy repeat, Prox proximal, Dist distal
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Table 1C). We defined complex as having multiple different NDDs.
Of ADHD cases with an NDD relevant CNV, a few were noteworthy
and highlight the clinical pleiotropy associated with many of these
variants. A male ascertained for ADHD (176004), who also had a
learning disability but no ASD, carried a duplication of 16p11.2,
which is known to be associated with ASD.8 We found deletions at
this locus in a female with SCZ, a male with ASD, and another male
with ADHD, but none in our OCD cases. A male diagnosed with
ADHD (206773), who carried a duplication of chromosome X
(Klinefelter syndrome), also had ASD, learning disability, language
delay, general anxiety disorder, and enuresis, all known feature of
Klinefelter syndrome.29 Male case 181220 with ADHD, with
15q11.2 duplication (BP1-BP2), also had ASD. Of OCD cases, a
male (OCD75-SB-1213) with a paternally inherited 62 kb duplica-
tion of DLGAP2 also had separation anxiety disorder, a Tourette
disorder with tic, oppositional defiant disorder, and panic
disorders and agoraphobia. Another male with OCD (OCD146-JS-
1254_188613), ADHD (inattentive subtype), and a Tourette
disorder with tic, had three different CNVs, impacting NLGN1,
DPP6, and PTPRN2. Of SCZ cases, a male (153030) with a 1.6 Mb
duplication of 16p13.11 also had a learning disorder but no ID
(details in Supplementary Table 1C). A female (213684) with SCZ
and a 549 kb deletion of NRXN1 also had moderate intellectual
disability. A male with SCZ (166808) with a 15q11-q13 duplication
had mild intellectual disability.
Cross-disorder gene discovery and genes in multiple cases in a
single disorder
We searched for genes, excluding those from regions of known
recurrent genomic disorders, that were affected in multiple cases
by CNVs. We first restricted analysis to brain-expressed genes that
are at least moderately constrained for LoF variants, (pLI > 0.45;
Fig. 2; Supplementary Table 1D). We searched these for genes
impacted by CNVs in at least two cases each, and found 20 genes
impacted by deletions. Notably, NRXN1 was impacted in 10 sub-
jects (three SCZ, six ASD, and one ADHD); deletions of 18p11.21
impacting novel candidate genes (GNAL, LDLRAD4, and SEH1L)
were in four cases (three ASD, one ADHD). Genes MKRN1 and
NRXN1
MYH9
MKRN1
ABR
DCTN2
DLGAP2
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LDLRAD4
SEH1L
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Fig. 2 Genes impacted by rare CNVs in more than one case. a) brain-expressed and moderately constrained genes (pLI > 0.45) impacted by
deletions in multiple cases, b) brain-expressed genes with duplication of their full-length transcript in more than one case
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MYH9 involved CNVs in ASD and SCZ cases. Eight genes – NRXN1,
GNAL, LDLRAD4, SEH1L, DLGAP2, DCTN2, GRID2, and KIF5A –
involved CNVs in ASD and ADHD cases. Only CNVs containing ABR
were shared between OCD and ASD, and no gene-containing
variants were shared between OCD and ADHD or OCD and SCZ.
Genes impacted by deletions in multiple ASD cases (only) were:
ASTN2, NRXN3, ANKS1B, GALNT13, DLC1, LAMP1, METRNL, PTPRK,
and SPOCK1 (Fig. 2; Supplementary Table 1D). Although ASTN2
deletions were previously reported in ADHD,30 in this study we
made no such observations. We saw no genes impacted by
deletions in multiple cases of ADHD, OCD, or SCZ, other than
those in the known genomic syndromes (Fig. 2; Supplementary
Table 1E).
We identified 53 brain-expressed genes impacted in multiple
cases by duplications of the entire longest transcript (Fig. 2;
Supplementary Table 1E). Examples included DNAJC15, GNG13,
CARHSP1, PCMTD2, RPS3A, and TMEM158 (Supplementary Table
1E). Most whole-gene duplications were from ASD cases, probably
due to the latter’s disproportionate representation. Examples of
genes with such variants in multiple disorders were: PCMTD2 in
ASD, OCD and SCZ; KNDC1 in ASD and SCZ; CARHSP1, PCMTD2,
SYNM, and EXOC3 in both ASD and OCD; and GNG13, MRPS33,
RPS3A, FAM69C, and CD24 in ASD and ADHD.
We found 38 genes duplicated in multiple ASD cases (only).
Examples included CDH15, UBTF, DUT, HYPK, ATXN7L3, and GLOD4.
Duplication of NDUFV1 and RIMKLB were each observed in two
ADHD cases (Fig. 2; Supplementary Table 1E). We found no
repeated full gene duplications in OCD or SCZ cases in this
collection.
Increased burden of rare CNVs impacting brain-expressed protein
coding genes and brain-expressed long non-coding RNA (lncRNA)
We sought rare CNVs impacting exons of lncRNAs and found these
in 1,130/2,691 cases (42%). Restricting to brain-expressed lncRNAs,
only 234/2,691 cases (8.7%) carried such rare CNVs. We tested for
the extent to which the protein coding genes and lncRNAs were
impacted by rare CNVs in cases compared with parents of cases.
We found a nearly significant excess in cases over controls of
deletions in protein-coding genes (p= 0.08; false discovery rate
(FDR)= 0.21), but not for lncRNAs (p > 0.1). We found no global
excess burden of duplications for protein-coding genes and
lncRNAs (p > 0.1). However, when focused on brain-expressed
elements, we observed a modest increase of rare deletions
impacting both protein-coding genes (p= 0.03; FDR= 0.19) and
lncRNAs (p= 0.06; FDR= 0.21). We then performed a multivariate
analysis to test whether the burden signal was from protein-
coding, lncRNAs, or both. This analysis showed a statistically
significant signal (p= 0.02) for deletions impacting protein-coding
genes, suggesting an overlap between the protein-coding and
lncRNA burden signal.
Given the increasing association of lncRNAs in disease, we
highlight two example of such genes identified in multiple
unrelated individuals. (i) AK127244: three subjects with ASD (1-
0045-004, 7-0103-003, and 1-0629-003) harbored 2p16.3 deletions
that directly disrupted the exonic sequence AK127244
(LOC730100). This is a 1.38 Mb non-coding RNA of unknown
function adjacent to NRXN1 and transcribed in the opposite
direction. Rare, inherited deletions intragenic to AK127244 have
been identified in five individuals with ASD. Such deletions have
been proposed as candidate factors for a broad range of
neuropsychiatric disorders including SCZ and affective disor-
der.16,31,32 We identified seven additional subjects here, five with
ASD and two with SCZ, with coding deletions of NRXN1 that
extend and disrupt the transcription start site and exonic
sequence of AK127244. (ii) PTCHD1-AS: we found five males with
ASD and deletions impacting exons of this gene (Table 3,
Supplementary Table 1C). Disruption of PTCHD1-AS has been
linked to ASD.33,34
Increased burden of CNVs impacting NDD genes in cases carrying
CNVs that impact genomic instability genes and fragile sites
We hypothesized that CNVs affecting genes involved in genome
stability might lead to a higher incidence of additional variants.
These subsequent variants could then add to the phenotypic
complexity, by impacting genes involved in the development and
functions of the nervous system. We therefore tested if individuals
carrying a CNV that impacts “genomic instability genes” (GIG-CNV)
have a higher burden of rare CNVs (measured as the number and
the cumulative length of rare CNVs per individual) than do
individuals not carrying such CNVs.35 We compiled a set of 958
protein coding “genomic instability genes” from the AmiGO
database.36
The “genomic instability genes” were not disproportionately
impacted by rare CNVs in cases compared with controls (parents
or unaffected individuals for this analysis) (p > 0.1). In individuals
who had a GIG-CNV, we found an increase in mean number of
CNVs (3.3 vs 2.1; p= 2.11 × 10-8) and cumulative length of rare
CNVs (4.4 Mb vs 315 kb; p= 2.11 × 10-8) compared to individuals
without a GIG-CNV. We observed a similar trend excluding CNVs
impacting the “genomic instability genes” from the burden
analysis (mean number of rare CNVs: 2.8 vs 2.1; p= 0.003;
cumulative length of rare CNVs: 564 kb vs 315 kb; p= 0.024). This
difference was even higher when considering only cases (i.e. not
controls)(mean number of rare CNVs: 2.9 vs 2.1; p= 0.013;
cumulative length of rare CNVs: 686 kb vs 358 kb; p= 0.051). We
also found a 2.77-fold increase in the number of cases with rare
CNVs impacting NDD-associated genes (NDD-CNV)(n= 1,160;
Supplementary Information) and a GIG-CNV (Fischer’s exact test,
p= 4.7 × 10−05, odds ratio: 2.77[CI:1.66–4.54]), compared with
cases with NDD-CNVs but without a GIG-CNV. We then excluded
individuals with aneuploidy or a CNV impacting both “genomic
instability genes” and NDD genes. We still observed the excess
number of cases with NDD-CNVs and GIG-CNVs over those with
NDD-CNVs only (odds ratio of 2.52[CI:1.50-4.16] (Fisher’s exact test,
p= 2.7 × 10-4)).
We then tested whether there was an increase CNV burden
among cases whose parents had a GIG-CNV. Such CNVs could
have been generated de novo anywhere previously in the
pedigree and had not necessarily arisen de novo in the affected
individual. We excluded the cases carrying a de novo GIG-CNV
that was not found in the parents. We found a higher average
number of rare CNVs in cases whose parents had GIG-CNVs
compared to cases whose parents did not (2.66 vs 2.10; p= 0.02).
We observed a similar trend for this global burden when
excluding the GIG-CNVs (2.49 vs 2.10; p= 0.08). However, we did
not observe an increased global burden in the cumulative length
of rare CNVs.
We then further investigated cases with de novo CNVs for
whom WGS data were available (n= 16, all from the ASD cohort).
We found no over-representation (p > 0.1) of cases with de novo
CNVs from families in which at least one parent carried a LoF
variant impacting a “genomic instability gene” (n= 10) compared
to other families (n= 6). Again, this was a small sample size. There
were notable examples of cases with de novo CNVs whose parents
had LoF variant(s) on “genomic instability genes”. (i) Case 1-0627-
007 had a paternally inherited frameshift deletion impacting
PALB2 (c.509_510del:p.R170fs). He also had a 1.9 Mb de novo
deletion in 16q23.3-q241 (Table 3, Supplementary Table 1C). (ii)
Case 2-1525-003 had a stop-gain mutation on PALB2 (c.G2712A:p.
W904X) and a 326 kb de novo duplication in 16p13.2. PALB2 plays
a role in homologous recombination and checkpoint response.37
(iii) Case 1-0181-004 had a paternally inherited variant in EXO1
(c.G2482T:p.E828X) and a 5.3 Mb de novo deletion in 3p14.1-p13.
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EXO1 functions in DNA replication, repair, and recombination
(OMIM:606063). (iv) The father of ASD case 2-1693-003 had a RAD1
variant (c.168_172del:p.A56fs) - a gene required for DNA replica-
tion and repair (OMIM: 603153). She carried a de novo 24 kb
deletion at Xp11.22.
We also studied the extent of de novo CNVs overlapping
genomic fragile sites. Of 33 de novo CNVs (excluding aneuploi-
dies), 25 (75.6%) overlapped fragile site regions (Supplementary
Table 1F). In addition, eleven of the de novo CNVs overlapped
long genes (>300 kb), a feature associated with fragile sites and
neuronal genes.38 Notably, five of these genes – MBD5, FAM19A1,
FOXP2, AUTS2, and DLGAP2 – are involved in neuron formation
and differentiation.
DISCUSSION
We generated a bioresource to investigate the contribution of rare
CNVs to the etiology of four NDDs – ASD, ADHD, OCD, and SCZ –
among 2,691 diagnosed cases. We found that 10.5% of these
cases carried CNVs with potential clinical relevance to NDDs. Of all
cases, 4.1% carried CNVs that were formally classified as clinically
significant or likely clinically significant, when evaluated according
to ACMG guidelines.26 We also found variant genes/regions that
were shared across some or all of the NDDs. Evidence included
recurrent or non-recurrent CNVs impacting the same genes in
cases with different NDDs, and in patients diagnosed with
multiple comorbid NDDs.
Of the four NDDs, ASD had the highest proportion of cases
with a clinically relevant CNV (11.4%). OCD cases had the lowest
proportion with identified CNVs (5.6%). Deletions of 22q11.21
were found in 6/204 SCZ cases (2.9%) - three with mild
intellectual disability - contributing to the relatively high
proportion of SCZ cases deemed to have a clinically relevant
CNV (10.8%). 22q11.2 deletions are expected to be identified in
about one in every 100-200 individuals with SCZ and about one
in 10 with dual diagnosis of SCZ and ID.11 The enrichment of the
SCZ cohort studied for ID likely contributed more to the
prevalence observed of 22q11.2 deletions. Of ADHD cases,
9.4% carried clinically relevant CNVs, which is slightly higher
than 8.9% previously reported using a different microarray
(Affymetrix SNP 6.0).10 We also found multiple clinically relevant
CNVs in 20/2,691 (0.74%) of NDD cases.
We found 17 aneuploidies (45,X; 47,XXY and 47,XYY) in cases
diagnosed with either ASD or ADHD (Table 2). The prevalence of
Turner syndrome (45,X) (n= 2) was 1/1,300 among our cases,
which is similar to previous reports.39 One had ADHD and the
other ASD, similar to other reports.39 Cases with 47,XXY (n= 5) or
47,XYY (n= 4) had diagnoses of either ASD or ADHD, similar to
previous reports.29 We found trisomy 21 (n= 6) only among ASD
patients.40 Large CNVs other than aneuploidies were found in 23/
2,691 (0.85%) cases, mainly in gene-rich regions of the genome.
Although we did not find aneuploidies in SCZ cases, they have
been reported in association with this phenotype previously.11,24
We found CNVs associated with known recurrent genomic
disorders in 4.3% of cases (Table 2). This signified an increase of
this type of CNVs among NDDs compared with that from a
community population (1.1% (52/4,817); unpublished data), but
similar to that of subjects with neurocognitive deficits in the UK
Biobank (3.8%).41
Known recurrent genomic disorders were distributed differently
among the four NDDs (Table 2; Fig. 1). We observed ASD in 80/115
(70%) of subjects with known recurrent genomic disorders, e.g.,
7q11.23 deletion, 16p11.2 distal deletion, and 22q11.21 duplica-
tions. The 5p deletion was unique to SCZ. Deletions of 2q37.3,
16p11.2 proximal duplications, and Xp22.3 deletions were found
only in ADHD, whereas 17q12 deletion was only found in OCD.
Duplications of 15q11-q13, deletions of 15q11.2 (BP1-BP2), and
16p13.11 duplications were observed among cases of all four
disorders (Fig. 1). Proximal duplications of 16p11.2 are found in up
to 1% of individuals with SCZ.11,24,42
When parents were available to determine origin, we found
5.6% of this subset of cases to have a de novo CNV (Table 2). The
highest de novo rate was for ASD (6.9%), consistent with previous
reports from 4.7 to 7.1%.43 For OCD, 1.8% had de novo CNVs,
which is higher than the rate found in the general population
(0.9–1.4%),43 but lower than 2.3% for OCD previously reported
from a larger sample size.13
We observed deletions and duplications, other than those
associated with known recurrent genomic disorders, in the same
genes in different NDDs, including some in multiple cases (Fig. 2;
Table 2, Supplementary Table 1D). Deletions impacted NRXN1 (in 9
males, 1 female) among ASD, ADHD, and SCZ cases (Fig. 2).
Similarly, we found deletions impacting GNAL, LDLRAD4, SEH1L,
DLGAP2, DCTN2, GRID2, and KIF5A among both ASD and ADHD
cases (Fig. 2).10
Disruptive variants in gene-sets involved in multiple intracellular
signaling pathways and DNA instability have been observed
previously in ASD.23 Variants in gene pathways associated with
DNA/“genomic instability” are increased in both ASD and SCZ.20
Consistent with these studies, we observed a 2.77-fold higher
proportion of cases with NDD-CNVs among those with GIG-CNVs,
than among those without.
This study had certain limitations. (i) Most cases, with the
exception of SCZ, were recruited as children or adolescents on
the basis of a specific diagnosis. ASD and ADHD have early
onset, and many participants would not have reached the age
for adolescent or adult-onset disorders, including OCD and SCZ.
It is possible that individuals with early onset conditions will
develop additional later-onset comorbidities. All SCZ cases in
the current study were adults. (ii) Recruitment was by clinicians
who focus on a single disorder. It is possible that some cases
may have had other NDDs, which were not reported. For
example, we had data on intellectual disability/IQ for the SCZ
cohort and for some cases with other NDDs. We searched the
genotype data for possible multiple ascertainment of any case
and found no examples of subjects that were recruited through
multiple disorders. We examined for non-primary phenotypes
for specific cases with variants in NDD-relevant genes. (iii) Due
to limitations of the technology, we studied CNVs only of a
certain size (>20 kb) for the majority of samples where we did
not have sequence data. Smaller CNVs and single nucleotide
polymorphisms also contribute to the etiology of NDDs,8,35 but
these would have been missed. A more sensitive technology
such as genome sequencing would allow more comprehensive
detection of all relevant variants.8,44 The dataset also needs to
be analyzed iteratively as more data and better analysis tools
become available.45
In summary, we highlighted clinically relevant CNVs found
through microarray data for ASD, ADHD, OCD, and SCZ. We also
demonstrated that identical CNVs or genes could potentially
contribute to the etiology of multiple NDDs, consistent with
previous reports,10,20,46,47 and providing a valuable resource for
comparison in other studies.
METHODS
Samples
This project was a part of a multilateral collaborative project to investigate
genetic etiology across four neurodevelopmental disorders: ADHD, ASD,
OCD, and SCZ. This study was approved by the Research Ethics Board at The
Hospital for Sick Children. A written informed consent was obtained from all
participants or substitute decision makers. CNVs were detected on the same
high-resolution microarray platform. The criteria for meeting a diagnosis of
ASD, ADHD, OCD, or SCZ were detailed in our previous publications8,10,13,23,24
with a few modifications for ADHD (see Supplementary Information). Data
from all OCD individuals and 139/435 (32%) of the SCZ cohort had been
M. Zarrei et al.
10
npj Genomic Medicine (2019)    26 Published in partnership with CEGMR, King Abdulaziz University
previously published,11,13 but we included them here for comparative
purposes (Supplementary Information). ADHD and ASD samples were not
previously published. Additional supportive evidence for cross-disorder
associations of selected CNVs came from our previously published
schizophrenia cohorts11,24 and an additional ADHD cohort10; all were
genotyped on the Affymetrix SNP 6.0 microarray (Table 3).
Genotyping and detection of rare variants
We extracted genomic DNA from saliva or blood and genotyped samples
on the Affymetrix CytoScan HD platform. Quality control and ancestry
assessment procedures were as discussed previously.25 Using PLINK
v1.90b2, we found 1,995 (74.1%) of cases to be of European ancestry
(Supplementary Table 1A).
CNVs were identified as previously described.13,25 Briefly, four different
algorithms were used to call high-confidence CNVs. These included the
Affymetrix Chromosome Analysis Suite, iPattern, BioDiscovery Nexus, and
Partek Genomics Suite. We defined a stringent set of variants of at least
20 kb wherein each was identified by at least two algorithms and spanned
by at least five consecutive probes (Supplementary Table 1B). We defined
rare CNVs as those present at no more than 0.1% frequency among 10,851
controls samples (detailed in Zarrei et al.25). We further restricted our list to
those with more than 75% overlap with copy-number stable regions,
according to our stringent CNV map of the human genome.2 We
confirmed clinically relevant CNVs (Tables 1, 2, Supplementary Table 1C)
(as defined below) using a SYBR® Green-based real-time quantitative PCR
assays, TaqMan® copy number assays or whole genome sequencing data
(if available). The genomic coordinates used are based on Human Genome
Build GRCh37/hg19.
Prioritizing variants relevant to NDDs and the NDD gene list
To focus on CNVs relevant to NDDs, we first selected those variants
coinciding with known recurrent genomic disorders, aneuploidies, and
large (>3Mb) deletions and duplications. We also analyzed whether rare
CNVs in our cases were similar to those in clinically relevant CNV databases
at The Department of Paediatric Laboratory Medicine, The Hospital for Sick
Children, comprising over 20,000 cases. We classified variants for their
clinical impact according to American College of Medical Genetics
guidelines.26 Our prioritized variants also included those impacting the
coding sequences of genes with sufficient evidence for being clinically
relevant to NDDs (Supplementary Information).
Cross-disorder gene discovery and genes in more than one case in
a single disorder
We searched for genes that were impacted by CNVs of 20 kb to 3Mb in
more than one case. Of these, we analyzed brain-expressed genes48 that
were impacted by rare deletions and that are moderately to strongly
constrained in the general population for LoF variants (as defined by a LoF
probability of > 0.4549; n= 1,116). We also analyzed genes whose full
transcript length was impacted by duplication.
Global burden test for protein-coding genes and lncRNAs
We performed a univariate analysis to test the global burden of variants
impacting coding sequences of protein-coding genes and all exons of
lncRNAs using a logistic regression model. We further tested a burden for
brain-expressed protein-coding genes (n= 3,666) and lncRNAs (n= 1,070)
to compare with those not expressed in the brain. Chromatin states from
the Roadmap Epigenomics Consortium50 were used to identify brain-
expressed genes (Supplementary Information). We defined controls as
parents of cases in the regression analysis. We used sex and the first three
principal components of population stratification calculated using PLINK as
covariates. The model was also corrected for the total length of CNVs.
Finally, we performed a multivariate analysis to investigate whether the
burden signals were from the same sets of CNVs as in the univariate
analysis (details in Supplementary Information). We considered p < 0.05 as
statistically significant. We also reported 0.05 < p < 0.1 as nearly significant.
Genomic instability and fragile sites
Replication stress can lead to CNV formation, and fragile sites. A recent
study using genome-wide CNVs20 demonstrated a link between DNA/
genomic integrity and ASD and SCZ. However, using a larger sample size
than the current study (1,108 ASD and 2,458 SCZ), they were unable to find
pathways enriched in ASD versus SCZ and vice versa. Given smaller
cohorts, we performed our analyses in a combined set of all four NDDs to
achieve an acceptable statistical power. We first investigated CNVs
impacting the coding sequences of genomic instability genes, looking
for change in the proportion of cases with rare CNVs in these genes,
compared with that of controls. The genomic instability genes comprised
958 protein coding genes identified from the AmiGO database36 by
searching for the following terms: DNA repair, DNA replication, genome
maintenance, DNA damage, and DNA integrity. We also tested for the
overall number of rare CNVs and total length of rare CNVs. We then
considered whether cases with perturbed genomic instability genes had a
different burden of rare CNVs in NDD genes compared to that in cases with
intact instability genes.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
DATA AVAILIBILITY
Relevant microarray data are deposited in the database of Genotypes and
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